Kalbe Farma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
. Vidjongtius
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.5yrs |
| CEO ownership | n/a |
| Management average tenure | 7.5yrs |
| Board average tenure | 7.5yrs |
Recent management updates
No updates
Recent updates
CEO
. Vidjongtius (60 yo)
7.5yrs
Tenure
Mr. Vidjongtius has been President Director of PT Kalbe Farma Tbk. since June 5, 2017 and has been its Director since 1997. He served as Corporate Secretary of PT.Kalbe Farma Tbk. since March 28, 2008 unt...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President Director | 7.5yrs | no data | no data | |
| Director of Human Resources | 17.9yrs | no data | no data | |
| Director of Corporate Business Development | 17.9yrs | no data | no data | |
| Head of Internal Audit Unit | 2.9yrs | no data | no data | |
| Corporate Secretary | 1.9yrs | no data | no data |
7.5yrs
Average Tenure
57yo
Average Age
Experienced Management: PTKF.F's management team is seasoned and experienced (7.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President Director | 27.9yrs | no data | no data | |
| Director of Corporate Business Development | 7.5yrs | no data | no data | |
| Commissioner | 16.9yrs | no data | no data | |
| President Commissioner | 7.5yrs | no data | 0.047% $ 1.7m | |
| Commissioner | 1.6yrs | no data | no data | |
| Director | 7.5yrs | no data | no data | |
| Independent Commissioner | no data | no data | no data | |
| Commissioner | 9.6yrs | no data | 0.20% $ 7.3m | |
| Director | 3.6yrs | no data | no data | |
| Independent Commissioner | 5.6yrs | no data | no data | |
| Director | 3.6yrs | no data | 0.00054% $ 19.6k | |
| Director | 1.9yrs | no data | no data |
7.5yrs
Average Tenure
60yo
Average Age
Experienced Board: PTKF.F's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:11 |
| End of Day Share Price | 2024/11/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PT Kalbe Farma Tbk. is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Helmy Kristanto | BNP Paribas Securities (Asia) |
| Swati Chopra | BofA Global Research |
| Jason Chandra | CGS International |